Title : TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.

Pub. Date : 2016 Sep

PMID : 27540244






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Tolvaptan (Jinarc ) is a vasopressin V2-receptor antagonist licensed for use to slow the progression of cyst development and renal insufficiency of ADPKD in adults with CKD stage 1 to 3 with evidence of rapidly progressing disease. Tolvaptan arginine vasopressin receptor 2 Homo sapiens